

The prognostic significance of protein arginine methyltransferase 6 expression in colon cancer


SUPPLEMENTARY MATERIALS




Supplementary Figure 1: Immunohistochemical PRMT6 staining CRC images. Images (100) of PRMT6 positive (A) and PRMT6-negative tumors (B) from stage III CRC patients.



Supplementary Figure 2: Interrelationship between PRMT6 and tumor suppressors in 24 matched samples from the primary CRC and adjacent normal tissues paired from the same patient. Expressions of PRMT6, p21 and p53 in patients with stage II (A) and stage III (B) were examined by western blotting. Densitometric intensity of each protein was normalized to β -actin. NDI indicates normalized densitometric intensity. Densitometric values corresponding to each protein were plotted and interrelationships between PRMT6 and p21 (C) and p53 (D) analyzed.



Supplementary Figure 3: Representative flow cytometry plots of siNC- and siPRMT6s-transfected CRC cells.



Supplementary Figure 4: Nuclear and cytoplasmic fractions of DLD1, HCT116 and DLD1 cells were prepared and analyzed by western blot. (A) The signal intensity of nuclear and cytoplasmic p21 was normalized by histone H3 signal and β-actin, respectively (B).

Supplementary Table 1: Sequences of primers used in the real-time PCR

Gene Name	Primer sequence
PRMT6	Forward 5'-TGCTGCCACCTCGCCTTTTC-3' Reverse 5'-TTGGTCTTCTCCTCGGTCTCC-3
p21	Forward 5'-GGCAGACCAGCATGACAGATT-3' Reverse 5'-GCGGATTAGGGCTTCCTCTT-3'
p53	Forward 5'-AGACTGGGTCTCGCTTTGTTG-3' Reverse 5'-AGGCAAAGGCTGCAGTAAGC-3
GAPDH	Forward 5'-ATCATCCCTGCCTCTACTGG-3' Reverse 5'-CTGCTTCACCACCTTCTTGA-3

	Number (%) (Total <i>N</i> = 586)		
Gender <i>n</i> (%)			
Female	221 (37.7)		
Male	365 (62.3)		
Median age (range, years)	59 (28–90)		
Location			
Colon	436 (74.4)		
Rectum	150 (25.6)		
Preoperative CEA (ng/ml) Median (range)	1.93 (0.14-148.32)		
AJCC stage			
IIA	269 (45.9)		
IIB	29 (4.9)		
IIC	10 (1.7)		
IIIA	38 (6.5)		
IIIB	240 (41.0)		
Tumor stage			
T1	14 (2.4)		
T2	26 (4.4)		
T3	476 (81.2)		
T4	70 (11.9)		
Nodal stage			
NO	308 (52.6)		
N1	216 (36.9)		
N2	62 (10.6)		
Cell type			
Well-differentiated	44 (7.5)		
Moderately-differentiated	488 (83.3)		
Poorly-differentiated	27 (4.6)		
Mucinous	25 (4.3)		
Signet ring cell	2 (0.3)		
Lymphatic invasion			
Negative	430 (73.4)		
Positive	156 (26.6)		
Vascular invasion			
Negative	394 (67.2)		
Positive	192 (32.8)		
Perineural invasion			
Negative	411 (70.1)		
Positive	175 (29.9)		
Adjuvant chemotherapy			
No	45 (7.7)		
Yes	458 (78.2)		
Undescribed	83 (14.2)		
PRMT6 expression			
Negative	447 (76.3)		
Positive	139 (23.7)		

Supplementary Table 2: Patients' demographics

Supplementary Table 3: Univariate and multivariate analyses for prognostic variables of diseasefree and overall survival using Cox-proportional-hazards regression

Predictors	Univariate	<i>p</i> -value	Multivariate	— <i>p</i> -value
	Ratio of risk (95% CI)		Ratio of risk (95% CI)	
Gender		0.862		
Female	1.000			
Male	1.039 (0.672–1.607)			
Age (years)		0.107		
< 60	1.000			
≥ 60	0.697 (0.449–1.081)			
Location		<u>< 0.001</u>		<u>0.006</u>
Colon	1.000		1.000	
Rectum	2.175 (1.420–3.333)		1.851 (1.196–2.865)	
CEA level		<u>0.001</u>		0.076
\leq 5 ng/ml	1.000		1.000	
> 5 ng/ml	2.105 (1.330–3.332)		1.548 (0.956–2.505)	
T stage		0.174		
T1–2	1.000			
T3-4	2.223 (0.703–7.033)			
N stage		<u>0.003</u>		0.155
NO	1.000		1.000	
N+	1.944 (1.257–3.005)		1.448 (0.870–2.410)	
Cell type		0.689		
WD/MD	1.000			
PD/MUC/SRC	0.854 (0.394–1.849)			
Lymphatic invasion		<u>< 0.001</u>		0.094
Negative	1.000		1.000	
Positive	2.448 (1.604–3.735)		1.526 (0.930-2.503)	
Vascular invasion		<u>< 0.001</u>		0.003
Negative	1.000		1.000	
Positive	3.334 (2.126–5.229)		2.216 (1.318-3.725)	
Perineural invasion		<u>0.010</u>		0.195
Negative	1.000		1.000	
Positive	2.223 (1.208–4.088)		1.527 (0.805–2.897)	
Adjuvant chemotherapy		<u>0.001</u>		< 0.001
Yes	1.000		1.000	
No/undescribed	2.133 (1.359–3.349)		2.557 (1.602-4.080)	
PRMT6 expression		<u>0.018</u>		<u>0.035</u>
Negative	1.000		1.000	
Positive	1.711 (1.096–2.673)		1.630 (1.034–2.569)	

(1) Disease-free survival

Predictors	Univariate Ratio of risk (95% CI)	<i>p</i> -value	Multivariate	<i>p</i> -value
			Ratio of risk (95% CI)	
Gender		0.441		
Female	1.000			
Male	1.295 (0.671–2.500)			
Age (years)		<u>0.014</u>		0.219
≤ 60	1.000		1.000	
> 60	2.191 (1.169–4.105)		1.509 (0.783–2.910)	
Location		0.124		
Colon	1.000			
Rectum	1.646 (0.872–3.107)			
CEA level		<u>< 0.001</u>		<u>0.003</u>
\leq 5 ng/ml	1.000		1.000	
> 5 ng/ml	3.482 (1.870-6.483)		2.654 (1.384–5.089)	
T stage		0.241		
T1–2	1.000			
T3-4	3.280 (0.451–23.863)			
N stage		<u>0.014</u>		0.282
NO	1.000		1.000	
N+	2.273 (1.177–4.388)		1.519 (0.710–3.254)	
Cell type		0.925		
WD/MD	1.000			
PD/Muc/SRC	1.051 (0.374–2.947)			
Lymphatic invasion		<u>< 0.001</u>		<u>0.013</u>
Negative	1.000		1.000	
Positive	3.732 (2.014–6.915)		2.389 (1.200-4.759)	
Vascular invasion		<u>< 0.001</u>		0.079
Negative	1.000		1.000	
Positive	3.230 (1.694–6.160)		1.895 (0.928–3.870)	
Perineural invasion		<u>0.001</u>		<u>0.012</u>
Negative	1.000		1.000	
Positive	3.676 (1.755–7.703)		2.694 (1.247–5.819)	
Adjuvant chemotherapy		<u>< 0.001</u>		<u><0.001</u>
Yes	1.000		1.000	
No/undescribed	5.662 (3.061–10.476)		5.615 (2.914–10.819)	
PRMT6 expression		0.353		
Negative	1.000			
Positive	1.376 (0.702–2.696)			

(2) Overall survival